Quantum Pharma launches third product from its Mucodis range of treatments

Mucodis dermal spray, which reached markets on Monday, was targetted at treating radiation-induced dermatitis, a condition which most radiotherapy patients experienced, the company said.

Andrew Scaife, Chief Executive of Quantum Pharma Plc, commented: " [...] There is a clear unmet need for this type of relief and we are confident that our products will have a significant effect on improving the patient's quality of life."

The severity of the skin condition could range from moderate to a severe type-2 skin reaction for 85.0% of the patients under treatment and was characterised by disorders such as inflammation to necrosis or peeling.

Every year, 352,000 patients in the UK were diagnosed with cancer, Quantum Pharma said in a statement.

The Mucodis range was meant to provide the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis, according to the company.

The launch of Mucodis dermal spray marked another positive step forward for Quantum, analysts at N+1 Singer said in a research note sent to clients.

"Evidence is building that the pipeline is now delivering and we expect further similar launches in due course. This should in turn result in a step change in profitability and cash generation and lead to a substantial re-rating of the shares."

As of 15:58 BST shares in Quantum Pharma were unchanged at 67.0p, giving the pharma firm a market capitalisation of £83.75m.